Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma1

This publication has 42 references indexed in Scilit:

• Synthesis, Characterization, and Cytotoxicity of a Novel Highly Charged Trinuclear Platinum Compound. Enhancement of Cellular Uptake with Charge
  Inorganic Chemistry, 2005
• Akt Activation Suppresses Chk2-Mediated, Methylating Agent–Induced G2 Arrest and Protects from Temozolomide-Induced Mitotic Catastrophe and Cellular Senescence
  Cancer Research, 2005
• Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma
  European Journal Of Cancer, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Cisplatin: mode of cytotoxic action and molecular basis of resistance
  Oncogene, 2003
• Reaction of Polynuclear Platinum Antitumor Compounds with Reduced Glutathione Studied by Multinuclear (¹H, ¹H−¹⁵N Gradient Heteronuclear Single-Quantum Coherence, and ¹⁹⁵Pt) NMR Spectroscopy
  Inorganic Chemistry, 2003
• Validating survivin as a cancer therapeutic target
  Nature Reviews Cancer, 2003
• A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464
  JBIC Journal of Biological Inorganic Chemistry, 2002
• Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model
  Journal of Neuro-Oncology, 1995